Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced

Lupus

Volumn 23, Issue 6, 2014, Pages 545-553

  Araujo Fernandez S ^a   Ahijon Lana M ^b   Isenberg, D A ^c  

^a HOSPITAL POVISA   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

anti histone antibodies; anti tumour necrosis factor ; Drug induced lupus; systemic lupus erythematosus

Indexed keywords

ANTINUCLEAR ANTIBODY; ATENOLOL; C REACTIVE PROTEIN; CARBAMAZEPINE; CHLORPROMAZINE; DOUBLE STRANDED DNA ANTIBODY; ETHOSUXIMIDE; HISTONE ANTIBODY; HYDRALAZINE; INTERFERON; ISONIAZID; METHYLDOPA; MINOCYCLINE; PENICILLAMINE; PHENYTOIN; PINDOLOL; PRIMIDONE; PROCAINAMIDE; PROPYLTHIOURACIL; QUINIDINE; SM ANTIBODY; SULFADIAZINE; THIAMAZOLE; TIMOLOL; TRIMETHADIONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG; VALPROIC ACID; ZONISAMIDE; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY TITER; ARTICLE; B LYMPHOCYTE ACTIVATION; CLINICAL FEATURE; DNA METHYLATION; DRUG CYTOTOXICITY; DRUG MECHANISM; ERYTHEMA NODOSUM; ERYTHROCYTE SEDIMENTATION RATE; GENETIC ASSOCIATION; HEPATOSPLENOMEGALY; HUMAN; HYPOCOMPLEMENTEMIA; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LUPUS LIKE SYNDROME; ONSET AGE; PAPULE; PATHOGENESIS; PERICARDITIS; PLEURA EFFUSION; PLEURISY; PRIORITY JOURNAL; PURPURA; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNITY; CHEMICALLY INDUCED; DRUG EFFECTS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; AUTOIMMUNITY; BIOLOGICAL PRODUCTS; HUMANS; INTERFERONS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899544856     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314523871     Document Type: Article

References (50)

1. Dalle Vedove C, Del Giglio M, Schena D, et al. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009 ; 301: 99-105
2. Pramatarov KD. Drug-induced lupus erythematosus. Clin Dermatol. 1998 ; 16: 367-377
3. Sarzi-Puttinni P, Atzeni F, Capsoni F, et al. Drug-induced lupus erythematosus. Autoinmunity. 2005 ; 38: 507-518
4. Vasoo S. Drug-induced lupus: an update. Lupus. 2006 ; 15: 757-761
5. Fritzler M, Rubin RL Duboiś Lupus erythematosus. 4 th edition. London: Lea and Febiger Philadelphia, 1993, pp. 442-456. Wallaco DJ Hahn BH, ed. London: Lea and Febiger Philadelphia ; 1993: 442-456.
6. Rubin RL. Drug-induced lupus. Toxicology. 2005 ; 209: 135-147
7. Chang C, Gershwin ME. Drug-induced lupus erythematosus. Drug Saf. 2011 ; 34: 357-374
8. Antonov D, Kazandjieva J, Etugov D, et al. Drug-induced lupus erythematosus. ClinDermatol. 2004 ; 22: 157-166
9. Pretel M, Marquès L, España A. Lupus eritematoso inducido por fármacos. Actas Dermo-Sifilio. 2014 ; 105: 18-30
10. Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann NY Acad Sci. 2007 ; 1108: 166-182
11. Aguirre-Zamorano MA, López-Pedrera R, Cuadrado-Lozano MJ. Lupus inducido por fármacos. Med Clin (Barc). 2010 ; 135: 124-129
12. Marzano AV, Vezzoli P, Crosti C. Drug-induced lupus: an uptodate on its dermatologic aspects. Lupus. 2009 ; 18: 935-940
13. Noël B. Lupus erythematosus and other autoimmune disease related to statin therapy: a systematic review. J Eur Acad Dermatol Venereol. 2007 ; 21: 17-24
14. Katz U, Zandman-Goddard G. Drug-induced lupus: an uptodate. Autoimmun Rev. 2010 ; 10: 46-50
15. Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med. 1985 ; 103: 49-51
16. Callen JP. Drug-induced cutaneous lupus erythematosus, a distinct syndrome that is frequently unrecognized. J Am Acad Dermatol. 2001 ;: 315-316
17. Sontheimer RD, Henderson CL, Grau RH. Drug-induced subacute cutaneous lupus erythematosus: a paradigm for bedside-to-bench patient-oriented translational clinical investigation. Arch Dermatol Res. 2009 ; 301: 65-70
18. Donnelly S, Levinson DA, Doyle DV. Systemic lupus erythematosus-like syndrome with focal proliferative glomerulonephritis during D-penicillamine therapy. Br J Rheumatol. 1993 ; 32: 251-253
19. Alloway JA, Salata MP. Quinidine-induced rheumatic syndromes. Semin Artritis Rheum. 1995 ; 24: 315-322
20. Graziadei IW, Obermoser GE, Sepp NT, et al. Drug induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus. 2003 ; 12: 409-412
21. Lawson TM, Amos N, Williams BD. Minocycline-induced lupus clinical features and response to rechallenge. Rheumatology. 2001 ; 40: 329-335
22. Williams VL, Cohen PR. TNF α antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF α antagonist. Int J Dermatol. 2011 ; 50: 619-625
23. Costa MF, Said NR, Zimmeermann B. Drug-induced lupus due to anti-tumor necrosis factorα agents. Semin Artritis Rheum. 2008 ; 37: 381-387
24. Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis factor αtherapy in 14 patients during an 8-year period at Mayo clinic. Mayo Clin Proc. 2009 ; 84: 979-984
25. De Bant M, Sibilia J, Le Löet X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor α therapy: a French national survey. Artritis Res Ther. 2005 ; 7: R545 - R551
26. De Rycke L, Kruithof E, Van Damme N, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Artritis Rheum. 2003 ; 48: 1015-1023
27. Gonnet-García C, Barnetche T, Richez C, et al. Antinuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNFαblockers. Clin Exp Rheumatol. 2008 ; 26: 401-407
28. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoinmune disease induced by TNF-targeted therapies. Análisis 233 cases. Medicine (Baltimore). 2007 ; 86: 242-251
29. Kerbleski JF, Gottlieb AB. Dermatological complications and safety of anti-TNF treatments. Gut. 2009 ; 58: 1033-1039
30. Almoallin H, Al-Ghamdi Y, Almaghrabi H, et al. Anti-tumor necrosis factor-α induced systemic lupus erythematosus. Open Rheumatol J. 2012 ; 6: 315-319
31. D'Auria F, Rovere-Querini P, Giazzon M, et al. Accumulation of plasma nucleosomas upon treatment with anti-tumour necrosis factor-α antibodies. J Intern Med. 2004 ; 255: 409-418
32. Ferraccioli G, Mecchia F, Di Poi E, et al. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis. 2002 ; 61: 358-361
33. Ramos-Casals M, Brito-Zeron P, Soto MJ, et al. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumato. 2008 ; 22: 847-861
34. Subramanian S, Yajnik V, Sands BE, et al. Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis. 2011 ; 17: 99-104
35. Bonaci-Nikolic B, Jeremic I, Andrejevic S, et al. Anti-double stranded DNA and lupus syndrome induced by interferon-â therapy in a patient with multiple sclerosis. Lupus. 2009 ; 18: 78-80
36. Sladkova V, Mares J, Lubenova B, et al. Drug-induced systemic lupus erythematosus in interferon beta-1b therapy. Neuro Endocrinol Lett. 2011 ; 32: 4-6
37. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 2000 ; 43: 1431-1442
38. Strasser A, Whittingham S, Vaux DL, et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci U S A. 1991 ; 88: 8661-8665
39. Goebel C, Vogel C, Wulferink M, et al. Procainamide, a drug causing lupus, induces prostaglandin H synthase-2 and formation of T cell-sensitizing drug metabolites in mouse macrophages. Chem Res Toxicol. 1999 ; 12: 488-500
40. Batchelor JR, Welsh KI, Tinoco RM, et al. Hydralazine induced systemic lupus erythematosus: Influence of HLA-DR and sex on susceptibility. Lancet. 1980 ; 24: 1107-1107
41. Mevorach D, Zhou JL, Song X, et al. Systemic exposure to irradiated apoptotic cells induces autoantibody production. J Exp Med. 1998 ; 188: 387-392
42. Ablin J, Verbovetski I, Trahtemberg U, et al. Quinidine and procainamide inhibit murine macrophage uptake of apoptotic and necrotic cells: a novel contributing mechanism of drug induced-lupus. Apoptosis. 2005 ; 10: 1009-1018
43. Zhou Y, Lu Q. DNA methylation in T cells from idiopathic lupus and drug-induced lupus patients. Autoimmun Rev. 2008 ; 7: 376-383
44. Gomez LM, Páez MC, Anaya JM. Epigenética y epigenómica de la artritis reumatoide. Rev Med. 2006 ; 14: 48-60
45. Quddus J, Johnson KJ, Gavalchin J, et al. Treating activated CD4+ T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to cause a lupus-like disease in syngeneic mice. J Clin Invest. 1993 ; 92: 38-53
46. Yung RL, Quddus J, Chrisp CE, et al. Mechanism of drug-induced lupus. I. Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol. 1995 ; 154: 3025-3035
47. Deng C, Lu Q, Zhang Z, et al. Hydralazine may induce autoimmunity by inhibiting extracelular signal-regulated kinase pathway signaling. Arthritis Rheum. 2003 ; 48: 746-756
48. Jamieson BD, Douek DC, Killian S, et al. Generation of functional thymocytes in the human adult. Immunity. 1999 ; 10: 569-575
49. Kretz-Rommel A, Duncan SR, Rubin RL. Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus. J Clin Invest. 1997 ; 99: 1888-1896
50. Sridhar MK, Abdulla A. Fatal lupus-like syndrome and ARDS induced by fluvastatin. Lancet. 1998 ; 352: 114-114